Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1183/13993003.01815-2017 http://scihub22266oqcxt.onion/10.1183/13993003.01815-2017 C5886843!5886843!29467203     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+Respir+J 2018 ; 51 (2): ä Nephropedia Template TP {{tp|p=29467203|t=2018. Sarcoidosis mortality in Sweden: a population-based cohort study |pdf=|usr=}}{{29467203}} gab.com Text Sarcoidosis mortality in Sweden: a population-based cohort study JO: Eur Respir J http://www.kidney.de/pget.php?&tw=1&pmid=29467203 #FOAvip We aimed to investigate sarcoidosis mortality in a large, population-based cohort, taking into account disease heterogeneity.Individuals with incident sarcoidosis (n=8207) were identified from the Swedish National Patient Register using International Classification of Disease codes (2003?2013). In a subset, cases receiving treatment ±3?months from diagnosis were identified from the Prescribed Drug Register. Nonsarcoidosis comparators from the general population were matched to cases 10:1 on birth year, sex and county. Individuals were followed for all-cause death in the Cause of Death Register. Adjusted mortality rates, rate differences and hazard ratios (HRs) were estimated, stratifying by age, sex and treatment status.The mortality rate was 11.0 per 1000?person-years in sarcoidosis versus 6.7 in comparators (rate difference 2.7 per 1000?person-years). The HR for death was 1.61 (95% CI 1.47?1.76), with no large variation by age or sex. For cases not receiving treatment within the first 3?months, the HR was 1.13 (95% CI 0.94?1.35). The HR was 2.34 (95% CI 1.99?2.75) for those receiving treatment.Individuals with sarcoidosis are at a higher risk of death compared to the general population. For the majority, the increased risk is small. However, patients whose disease leads to treatment around diagnosis have a two-fold increased risk of death. Future interventions should focus on this vulnerable group. Twit Text FOAVip Sarcoidosis mortality in Sweden: a population-based cohort study ????Eur Respir J http://www.kidney.de/pget.php?&tw=1&pmid=29467203 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29467203 #FOAvip English Wikipedia <ref>{{Cite pmid|29467203}}</ref> Sarcoidosis mortality in Sweden: a population-based cohort study #MMPMID29467203 Rossides M; Kullberg S; Askling J; Eklund A; Grunewald J; Arkema EV Eur Respir J 2018[Feb]; 51 (2): ä PMID29467203show ga We aimed to investigate sarcoidosis mortality in a large, population-based cohort, taking into account disease heterogeneity.Individuals with incident sarcoidosis (n=8207) were identified from the Swedish National Patient Register using International Classification of Disease codes (2003?2013). In a subset, cases receiving treatment ±3?months from diagnosis were identified from the Prescribed Drug Register. Nonsarcoidosis comparators from the general population were matched to cases 10:1 on birth year, sex and county. Individuals were followed for all-cause death in the Cause of Death Register. Adjusted mortality rates, rate differences and hazard ratios (HRs) were estimated, stratifying by age, sex and treatment status.The mortality rate was 11.0 per 1000?person-years in sarcoidosis versus 6.7 in comparators (rate difference 2.7 per 1000?person-years). The HR for death was 1.61 (95% CI 1.47?1.76), with no large variation by age or sex. For cases not receiving treatment within the first 3?months, the HR was 1.13 (95% CI 0.94?1.35). The HR was 2.34 (95% CI 1.99?2.75) for those receiving treatment.Individuals with sarcoidosis are at a higher risk of death compared to the general population. For the majority, the increased risk is small. However, patients whose disease leads to treatment around diagnosis have a two-fold increased risk of death. Future interventions should focus on this vulnerable group. äSarcoidosis mortality in Sweden: a population-based cohort study (epmc).pdf DeepDyve Pubget Overpricing